Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Immunotherapy is associated with improved survival and decreased neurologic death after SRS for brain metastases from lung and melanoma primaries.

Lanier CM, Hughes R, Ahmed T, LeCompte M, Masters AH, Petty WJ, Ruiz J, Triozzi P, Su J, O'Neill S, Watabe K, Cramer CK, Laxton AW, Tatter SB, Wang G, Whitlow C, Chan MD.

Neurooncol Pract. 2019 Sep;6(5):402-409. doi: 10.1093/nop/npz004. Epub 2019 Feb 5.

PMID:
31555455
2.

Limited-Stage Small Cell Lung Cancer: Is Prophylactic Cranial Irradiation Necessary?

Farris MK, Wheless WH, Hughes RT, Soike MH, Masters AH, Helis CA, Chan MD, Cramer CK, Ruiz J, Lycan T, Petty WJ, Ahmed T, Leyrer CM, Blackstock AW.

Pract Radiat Oncol. 2019 Jul 2. pii: S1879-8500(19)30185-7. doi: 10.1016/j.prro.2019.06.014. [Epub ahead of print]

PMID:
31271904
3.

Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial.

Dohm A, Su J, McTyre ER, Taylor JM, Miller LD, Petty WJ, Xing F, Lo HW, Metheny-Barlow LJ, O'Neill S, Bellinger C, Dotson T, Pasche B, Watabe K, Chan MD, Ruiz J.

Int J Biol Markers. 2019 Mar;34(1):90-97. doi: 10.1177/1724600818803104. Epub 2019 Mar 10.

PMID:
30854931
4.

Cure of Oligometastatic Classic Biphasic Pulmonary Blastoma Using Aggressive Tri-modality Treatment: Case Series and Review of the Literature.

Lewis JA, Petty WJ, Urbanic J, Bernstein ED, Ahmed T.

Cureus. 2018 Nov 13;10(11):e3586. doi: 10.7759/cureus.3586. Review.

5.

Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis.

Bonomi M, Ahmed T, Addo S, Kooshki M, Palmieri D, Levine BJ, Ruiz J, Grant S, Petty WJ, Triozzi PL.

Oncol Lett. 2019 Jan;17(1):1349-1356. doi: 10.3892/ol.2018.9724. Epub 2018 Nov 19.

6.

Feasibility of lung cancer RNA acquisition from a single transbronchial or transthoracic needle pass (FASTT trial).

Dotson T, Bellinger C, Su J, Hansen K, Parks GE, Cappellari JO, Craddock L, Clark H, Howard C, Petty WJ, Prakash B, Watabe K, Chan M, Hovda J, Miller LD, Ruiz J.

Lung Cancer. 2019 Jan;127:6-11. doi: 10.1016/j.lungcan.2018.11.023. Epub 2018 Nov 20.

PMID:
30642553
7.

Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age.

Ruiz J, Miller AA, Tooze JA, Crane S, Petty WJ, Gajra A, Klepin HD.

J Geriatr Oncol. 2019 Jan;10(1):48-54. doi: 10.1016/j.jgo.2018.06.007. Epub 2018 Jul 10.

8.

Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer.

Petty WJ, Urbanic JJ, Ahmed T, Hughes R, Levine B, Rusthoven K, Papagikos M, Ruiz JR, Lally BE, Chan M, Clark H, D'Agostino RB Jr, Blackstock AW.

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):527-535. doi: 10.1016/j.ijrobp.2018.06.400. Epub 2018 Jul 10.

9.

Severe neurologic complications of immune checkpoint inhibitors: a single-center review.

Mancone S, Lycan T, Ahmed T, Topaloglu U, Dothard A, Petty WJ, Strowd RE.

J Neurol. 2018 Jul;265(7):1636-1642. doi: 10.1007/s00415-018-8890-z. Epub 2018 May 14.

PMID:
29761297
10.

Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1.

Liu L, Ruiz J, O'Neill SS, Grant SC, Petty WJ, Yang M, Chen K, Topaloglu U, Pasche B, Zhang W.

Mol Cancer. 2018 Apr 12;17(1):81. doi: 10.1186/s12943-018-0832-y.

11.

Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?

Yang M, Forbes ME, Bitting RL, O'Neill SS, Chou PC, Topaloglu U, Miller LD, Hawkins GA, Grant SC, DeYoung BR, Petty WJ, Chen K, Pasche BC, Zhang W.

Ann Oncol. 2018 Feb 1;29(2):311-323. doi: 10.1093/annonc/mdx766. Review.

12.

Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center.

Kytola V, Topaloglu U, Miller LD, Bitting RL, Goodman MM, D Agostino RB Jr, Desnoyers RJ, Albright C, Yacoub G, Qasem SA, DeYoung B, Thorsson V, Shmulevich I, Yang M, Shcherban A, Pagni M, Liu L, Nykter M, Chen K, Hawkins GA, Grant SC, Petty WJ, Alistar AT, Levine EA, Staren ED, Langefeld CD, Miller V, Singal G, Petro RM, Robinson M, Blackstock W, Powell BL, Wagner LI, Foley KL, Abraham E, Pasche B, Zhang W.

Theranostics. 2017 Jul 12;7(11):2914-2923. doi: 10.7150/thno.20355. eCollection 2017.

13.

Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.

Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, Robinson M, Bitting RL, Thomas A, Alistar AT, Desnoyers RJ, Goodman M, Albright C, Porosnicu M, Vatca M, Qasem SA, DeYoung B, Kytola V, Nykter M, Chen K, Levine EA, Staren ED, D'Agostino RB Jr, Petro RM, Blackstock W, Powell BL, Abraham E, Pasche B, Zhang W.

J Hematol Oncol. 2017 May 4;10(1):100. doi: 10.1186/s13045-017-0468-1.

14.

The Effects of smoking status and smoking history on patients with brain metastases from lung cancer.

Shenker RF, McTyre ER, Ruiz J, Weaver KE, Cramer C, Alphonse-Sullivan NK, Farris M, Petty WJ, Bonomi MR, Watabe K, Laxton AW, Tatter SB, Warren GW, Chan MD.

Cancer Med. 2017 May;6(5):944-952. doi: 10.1002/cam4.1058. Epub 2017 Apr 12.

15.

Phase II Trial of Angiotensin-(1-7) for the Treatment of Patients with Metastatic Sarcoma.

Savage PD, Lovato J, Brosnihan KB, Miller AA, Petty WJ.

Sarcoma. 2016;2016:4592768. Epub 2016 Nov 8.

16.

A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma.

Lycan TW, Pardee TS, Petty WJ, Bonomi M, Alistar A, Lamar ZS, Isom S, Chan MD, Miller AA, Ruiz J.

PLoS One. 2016 Oct 12;11(10):e0164244. doi: 10.1371/journal.pone.0164244. eCollection 2016.

17.

The Impact of Hospice Services in the Care of Patients with Advanced Stage Nonsmall Cell Lung Cancer.

Duggan KT, Hildebrand Duffus S, D'Agostino RB Jr, Petty WJ, Streer NP, Stephenson RC.

J Palliat Med. 2017 Jan;20(1):29-34. Epub 2016 Aug 25.

PMID:
27559623
18.

Is a Clinical Target Volume (CTV) Necessary in the Treatment of Lung Cancer in the Modern Era Combining 4-D Imaging and Image-guided Radiotherapy (IGRT)?

Kilburn JM, Lucas JT, Soike MH, Ayala-Peacock DN, Blackstock AW, Hinson WH, Munley MT, Petty WJ, Urbanic JJ.

Cureus. 2016 Jan 23;8(1):e466. doi: 10.7759/cureus.466.

19.

Image guided radiation therapy may result in improved local control in locally advanced lung cancer patients.

Kilburn JM, Soike MH, Lucas JT, Ayala-Peacock D, Blackstock W, Isom S, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ.

Pract Radiat Oncol. 2016 May-Jun;6(3):e73-e80. doi: 10.1016/j.prro.2015.10.004. Epub 2015 Oct 22.

20.

Clinical perspective on PROSE: does VeriStrat testing improve selection of second-line treatment for patients with non-small cell lung cancer?

Ruiz J, Petty WJ.

Ann Transl Med. 2015 Mar;3(3):31. doi: 10.3978/j.issn.2305-5839.2015.01.22. No abstract available.

21.

Low-Dose CT Lung Cancer Screening Practices and Attitudes among Primary Care Providers at an Academic Medical Center.

Lewis JA, Petty WJ, Tooze JA, Miller DP, Chiles C, Miller AA, Bellinger C, Weaver KE.

Cancer Epidemiol Biomarkers Prev. 2015 Apr;24(4):664-70. doi: 10.1158/1055-9965.EPI-14-1241. Epub 2015 Jan 22.

22.

Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer.

Kilburn JM, Lester SC, Lucas JT Jr, Soike MH, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ.

J Thorac Oncol. 2014 Apr;9(4):572-6. doi: 10.1097/JTO.0000000000000086.

23.

Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone.

Lewis JA, Petty WJ, Harmon M, Peacock JE, Valente K, Owen J, Pirmohamed M, Lesser GJ.

J Oncol Pharm Pract. 2015 Jun;21(3):220-3. doi: 10.1177/1078155214524085. Epub 2014 Feb 27.

PMID:
24576944
24.

Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment.

Kilburn JM, Kuremsky JG, Blackstock AW, Munley MT, Kearns WT, Hinson WH, Lovato JF, Miller AA, Petty WJ, Urbanic JJ.

Radiother Oncol. 2014 Mar;110(3):505-10. doi: 10.1016/j.radonc.2013.11.017. Epub 2014 Jan 17.

25.

Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer.

Petty WJ, Laudadio J, Brautnick L, Lovato J, Dotson T, Streer NP, Weaver KE, Miller AA.

Int J Oncol. 2013 Dec;43(6):2057-63. doi: 10.3892/ijo.2013.2122. Epub 2013 Oct 3.

26.

Tumor histology predicts patterns of failure and survival in patients with brain metastases from lung cancer treated with gamma knife radiosurgery.

Kuremsky JG, Urbanic JJ, Petty WJ, Lovato JF, Bourland JD, Tatter SB, Ellis TL, McMullen KP, Shaw EG, Chan MD.

Neurosurgery. 2013 Oct;73(4):641-7; discussion 647. doi: 10.1227/NEU.0000000000000072.

27.

Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.

Socinski MA, Stinchcombe TE, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Khandani A, Morris DE.

J Clin Oncol. 2012 Nov 10;30(32):3953-9. doi: 10.1200/JCO.2012.41.9820. Epub 2012 Oct 8.

PMID:
23045594
28.

Reverse translation of phase I biomarker findings links the activity of angiotensin-(1-7) to repression of hypoxia inducible factor-1α in vascular sarcomas.

Petty WJ, Aklilu M, Varela VA, Lovato J, Savage PD, Miller AA.

BMC Cancer. 2012 Sep 11;12:404. doi: 10.1186/1471-2407-12-404.

29.

High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer.

Petty WJ, Voelzke WR, Urbanic JJ, Varela VA, Waller LL, Swift CB, Graham RM, Memoli VA, Dragnev KH.

Lung Cancer. 2011 Dec;74(3):384-91. doi: 10.1016/j.lungcan.2011.04.004. Epub 2011 May 8.

PMID:
21555162
30.

Effects of continued tobacco use during treatment of lung cancer.

Waller LL, Weaver KE, Petty WJ, Miller AA.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1569-75. doi: 10.1586/era.10.140. Review.

PMID:
20942628
31.

A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer.

Center B, Petty WJ, Ayala D, Hinson WH, Lovato J, Capellari J, Oaks T, Miller AA, Blackstock AW.

J Thorac Oncol. 2010 Jan;5(1):69-74. doi: 10.1097/JTO.0b013e3181c59a0e.

32.

Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone.

Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM.

Clin Cancer Res. 2009 Dec 1;15(23):7398-404. doi: 10.1158/1078-0432.CCR-09-1957. Epub 2009 Nov 17.

33.

Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke.

Waller LL, Miller AA, Petty WJ.

Lung Cancer. 2010 Jan;67(1):12-6. doi: 10.1016/j.lungcan.2009.08.014. Review.

PMID:
19762110
34.

Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.

Hughes AN, O'Brien ME, Petty WJ, Chick JB, Rankin E, Woll PJ, Dunlop D, Nicolson M, Boinpally R, Wolf J, Price A.

J Clin Oncol. 2009 Mar 10;27(8):1220-6. doi: 10.1200/JCO.2008.19.3995. Epub 2009 Jan 21.

35.

Distinct functions of retinoic acid receptor beta isoforms: implications for targeted therapy.

Swift CB, Hays JL, Petty WJ.

Endocr Metab Immune Disord Drug Targets. 2008 Mar;8(1):47-50. Review.

PMID:
18393922
36.

Targeting the epidermal growth factor receptor in high-grade astrocytomas.

Voelzke WR, Petty WJ, Lesser GJ.

Curr Treat Options Oncol. 2008 Feb;9(1):23-31. doi: 10.1007/s11864-008-0053-5. Epub 2008 Feb 5. Review.

PMID:
18247132
37.

The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database.

Lally BE, Detterbeck FC, Geiger AM, Thomas CR Jr, Machtay M, Miller AA, Wilson LD, Oaks TE, Petty WJ, Robbins ME, Blackstock AW.

Cancer. 2007 Aug 15;110(4):911-7.

38.

A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer.

Petty WJ, Knight SN, Mosley L, Lovato J, Capellari J, Tucker R, Blackstock AW, Miller MS, Miller AA.

J Thorac Oncol. 2007 Mar;2(3):197-202.

39.

A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.

Dragnev KH, Petty WJ, Shah SJ, Lewis LD, Black CC, Memoli V, Nugent WC, Hermann T, Negro-Vilar A, Rigas JR, Dmitrovsky E.

Clin Cancer Res. 2007 Mar 15;13(6):1794-800.

40.

Frequent requirement of hedgehog signaling in non-small cell lung carcinoma.

Yuan Z, Goetz JA, Singh S, Ogden SK, Petty WJ, Black CC, Memoli VA, Dmitrovsky E, Robbins DJ.

Oncogene. 2007 Feb 15;26(7):1046-55. Epub 2006 Aug 14.

PMID:
16909105
41.

Bexarotene and erlotinib for aerodigestive tract cancer.

Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E.

J Clin Oncol. 2005 Dec 1;23(34):8757-64.

PMID:
16314636
42.

A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis.

Petty WJ, Li N, Biddle A, Bounds R, Nitkin C, Ma Y, Dragnev KH, Freemantle SJ, Dmitrovsky E.

J Natl Cancer Inst. 2005 Nov 16;97(22):1645-51.

PMID:
16288117
43.

Nonclassical retinoids and lung carcinogenesis.

Dragnev KH, Petty WJ, Ma Y, Rigas JR, Dmitrovsky E.

Clin Lung Cancer. 2005 Jan;6(4):237-44. Review.

PMID:
15694016
44.

Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.

Petty WJ, Dragnev KH, Memoli VA, Ma Y, Desai NB, Biddle A, Davis TH, Nugent WC, Memoli N, Hamilton M, Iwata KK, Rigas JR, Dmitrovsky E.

Clin Cancer Res. 2004 Nov 15;10(22):7547-54.

45.

Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention.

Pitha-Rowe I, Petty WJ, Feng Q, Koza-Taylor PH, Dimattia DA, Pinder L, Dragnev KH, Memoli N, Memoli V, Turi T, Beebe J, Kitareewan S, Dmitrovsky E.

Cancer Res. 2004 Nov 1;64(21):8109-15.

46.

Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy.

Dragnev KH, Pitha-Rowe I, Ma Y, Petty WJ, Sekula D, Murphy B, Rendi M, Suh N, Desai NB, Sporn MB, Freemantle SJ, Dmitrovsky E.

Clin Cancer Res. 2004 Apr 1;10(7):2570-7.

47.

The role of docetaxel in nonplatinum-based combination chemotherapy for non-small-cell lung cancer.

Petty WJ, Rothmann J, Dragnev KH, Rigas JR.

Clin Lung Cancer. 2002 May;3 Suppl 2:S12-6.

PMID:
14720342
48.

Retinoid targets in cancer therapy and chemoprevention.

Dragnev KH, Petty WJ, Dmitrovsky E.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S150-6. Review.

PMID:
14508093
49.

Retinoid target genes in acute promyelocytic leukemia.

Pitha-Rowe I, Petty WJ, Kitareewan S, Dmitrovsky E.

Leukemia. 2003 Sep;17(9):1723-30. Review.

PMID:
12970771
50.

Cyclin D1 as a target for chemoprevention.

Petty WJ, Dragnev KH, Dmitrovsky E.

Lung Cancer. 2003 Aug;41 Suppl 1:S155-61. Review.

PMID:
12867074

Supplemental Content

Loading ...
Support Center